Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BLD044
MIFTS: 57

Bladder Disease

Categories: Blood diseases, Nephrological diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Bladder Disease

About this section

MalaCards integrated aliases for Bladder Disease:

Name: Bladder Disease 39 12 15 17
Urinary Bladder Diseases 45 74
Bladder Diseases 56 44
Urinary Bladder Disease 12

Classifications:

MalaCards categories:
Anatomical: Nephrological diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:365
ICD9CM 36 596.9
MeSH 45 D001745
NCIt 51 C2900
SNOMED-CT 69 42643001
UMLS 74 C0005686
Sources

Summaries for Bladder Disease

About this section
MedlinePlus : 44 The bladder is a hollow organ in your lower abdomen that stores urine. Many conditions can affect your bladder. Some common ones are Cystitis - inflammation of the bladder, often from an infection Urinary incontinence - loss of bladder control Overactive bladder - a condition in which the bladder squeezes urine out at the wrong time Interstitial cystitis - a chronic problem that causes bladder pain and frequent, urgent urination Bladder cancer Doctors diagnose bladder diseases using different tests. These include urine tests, x-rays, and an examination of the bladder wall with a scope called a cystoscope. Treatment depends on the cause of the problem. It may include medicines and, in severe cases, surgery. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Bladder Disease, also known as urinary bladder diseases, is related to cystitis and interstitial cystitis, and has symptoms including bladder fullness sensation An important gene associated with Bladder Disease is TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1), and among its related pathways/superpathways are Glioma and Gastric cancer. The drugs Hyaluronic acid and Nitrofurantoin have been mentioned in the context of this disorder. Affiliated tissues include prostate, testes and spinal cord, and related phenotypes are homeostasis/metabolism and behavior/neurological

Disease Ontology : 12 A urinary system disease that is located in the bladder.

Wikipedia : 77 Urinary bladder disease includes urinary bladder inflammation such as cystitis, bladder rupture and... more...

Sources

Related Diseases for Bladder Disease

About this section

Diseases related to Bladder Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 104)
# Related Disease Score Top Affiliating Genes
1 cystitis 32.4 HBEGF TRPV1 UPK3A
2 interstitial cystitis 29.9 CDH1 HBEGF TRPV1 UPK3A
3 bladder urothelial carcinoma 29.8 CDH1 FGFR3 TP53 UPK3A
4 transitional cell carcinoma 29.6 CDH1 CDKN2A FGFR3 TP53 UPK2 UPK3A
5 gallbladder disease 11.0
6 bladder papillary transitional cell neoplasm 10.5 FGFR3 TERT TP53
7 urinary tract papillary transitional cell benign neoplasm 10.5 FGFR3 TERT TP53
8 male reproductive system disease 10.5 CDH1 TP53 TRPV1
9 cerebral convexity meningioma 10.5 CDH1 TP53
10 non-invasive bladder papillary urothelial neoplasm 10.5 FGFR3 TP53 UPK3A
11 toxic oil syndrome 10.5 GSTM1 IDO1 NAT2
12 bladder squamous cell carcinoma 10.4 CDKN2A TP53 UPK2
13 mutagen sensitivity 10.4 GSTM1 NAT2 TP53
14 bowenoid papulosis 10.4 CDKN2A TERT
15 oral leukoplakia 10.4 CDKN2A GSTM1 TP53
16 papilloma 10.4 CDKN2A FGFR3 TP53
17 supratentorial cancer 10.4 CDKN2A TERT TP53
18 vulvar disease 10.4 CDKN2A TP53 UPK3A
19 invasive bladder transitional cell carcinoma 10.4 TP53 UPK3A
20 esophageal disease 10.4 CDKN2A TP53 TRPV1
21 retroperitoneum carcinoma 10.4 CDKN2A UPK2
22 cerebrum cancer 10.4 CDKN2A TERT TP53
23 cervix carcinoma 10.4 CDKN2A FGFR3 TP53
24 keratinizing squamous cell carcinoma 10.4 CDKN2A TP53
25 tongue disease 10.4 CDH1 CDKN2A TP53
26 vulva cancer 10.4 CDKN2A TP53 UPK3A
27 tonsil cancer 10.4 CDH1 CDKN2A TP53
28 stomach disease 10.4 CDH1 TP53 TRPV1
29 upper respiratory tract disease 10.4 CDKN2A TP53 TRPV1
30 pre-malignant neoplasm 10.4 CDH1 CDKN2A TP53
31 oropharynx cancer 10.4 CDH1 CDKN2A TP53
32 squamous cell papilloma 10.4 CD274 CDKN2A TP53
33 intestinal disease 10.4 CDH1 TP53 TRPV1
34 spitz nevus 10.4 CDKN2A TP53
35 in situ carcinoma 10.4 CDH1 CDKN2A TP53
36 nasopharyngeal disease 10.4 CDH1 CDKN2A TP53
37 central nervous system lymphoma 10.4 CD274 CDKN2A TP53
38 cervix disease 10.4 CDH1 CDKN2A TP53
39 epstein-barr virus-associated gastric carcinoma 10.4 CD274 CDH1 CDKN2A
40 ureteral disease 10.4 CDH1 SLC3A1 SLC7A9 UPK3A
41 cholecystitis 10.4 CDH1 CDKN2A TP53
42 cervical squamous cell carcinoma 10.4 CDH1 CDKN2A TP53
43 laryngeal squamous cell carcinoma 10.4 CDH1 CDKN2A TERT TP53
44 uterine anomalies 10.4 CDH1 CDKN2A TP53
45 acute lymphocytic leukemia 10.4 CDKN2A GSTM1 TP53
46 tongue cancer 10.4 CDH1 CDKN2A TP53
47 oral cavity cancer 10.4 CDH1 GSTM1 TP53
48 female reproductive system disease 10.3 CDH1 CDKN2A TP53 TRPV1
49 renal hypodysplasia/aplasia 3 10.3 FGFR3 UPK3A
50 reproductive system disease 10.3 CDH1 CDKN2A TP53 TRPV1

Comorbidity relations with Bladder Disease via Phenotypic Disease Network (PDN):


Acute Cystitis Bladder Neck Obstruction
Prostatic Hypertrophy

Graphical network of the top 20 diseases related to Bladder Disease:



Diseases related to Bladder Disease
Sources

Symptoms & Phenotypes for Bladder Disease

About this section

UMLS symptoms related to Bladder Disease:


bladder fullness sensation

MGI Mouse Phenotypes related to Bladder Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.33 CD274 CDH1 CDKN2A CHRM3 ELAVL3 ERCC6
2 behavior/neurological MP:0005386 10.22 CD274 CDKN2A CHRM3 ELAVL3 ERCC6 FGFR3
3 cellular MP:0005384 10.2 BLNK CD274 CDH1 CDKN2A ERCC6 FGFR3
4 growth/size/body region MP:0005378 10.17 CDH1 CDKN2A CHRM3 ERCC6 FGFR3 HBEGF
5 immune system MP:0005387 10.15 BLNK CD274 CDH1 CDKN2A ERCC6 FGFR3
6 mortality/aging MP:0010768 10.07 BLNK CD274 CDH1 CDKN2A ELAVL3 ERCC6
7 integument MP:0010771 9.92 CD274 CDH1 CDKN2A ERCC6 FGFR3 HBEGF
8 muscle MP:0005369 9.7 CDKN2A CHRM3 ERCC6 HBEGF IDO1 SLC3A1
9 neoplasm MP:0002006 9.56 BLNK CDH1 CDKN2A ERCC6 FGFR3 TERT
10 renal/urinary system MP:0005367 9.28 CHRM3 FGFR3 IDO1 SLC3A1 SLC7A9 TP53
Sources

Drugs & Therapeutics for Bladder Disease

About this section

Drugs for Bladder Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 644)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 2,Not Applicable 9004-61-9 53477741
2
Nitrofurantoin Approved, Vet_approved Phase 4,Phase 3,Phase 2 67-20-9 5353830
3
Fosfomycin Approved Phase 4,Not Applicable 23155-02-4 446987
4
Mirabegron Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 223673-61-8 9865528
5
Acetylcholine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 51-84-3 187
6
Fesoterodine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 286930-03-8, 286930-02-7 6918558
7
Oxybutynin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 5633-20-5 4634
8
Doxazosin Approved Phase 4 74191-85-8 3157
9
Alverine Approved, Investigational Phase 4 150-59-4 3678
10
Mebeverine Approved, Investigational Phase 4 3625-06-7 62887
11
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Not Applicable 59467-70-8 4192
12
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Not Applicable 437-38-7 3345
13
Propiverine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 60569-19-9 4942
14
Tamsulosin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 106133-20-4 129211
15
Trimethoprim Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 738-70-5 5578
16
Sulfamethoxazole Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 723-46-6 5329
17
Epirubicin Approved Phase 4,Phase 3,Phase 2,Not Applicable 56420-45-2 41867
18
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
19
Diclofenac Approved, Vet_approved Phase 4,Phase 3 15307-86-5 3033
20
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 15663-27-1 2767 441203 84093
21
Oxytocin Approved, Vet_approved Phase 4 50-56-6 53477758 439302
22
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
23
Ibuprofen Approved Phase 4 15687-27-1 3672
24
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Not Applicable 85721-33-1 2764
25
Citalopram Approved Phase 4 59729-33-8 2771
26
Azithromycin Approved Phase 4 83905-01-5 447043 55185
27
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
28
Darifenacin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 133099-04-4 444031
29
Silodosin Approved Phase 4 160970-54-7
30
Amoxicillin Approved, Vet_approved Phase 4,Phase 3 26787-78-0 33613
31
Cefixime Approved, Investigational Phase 4,Phase 3 79350-37-1 5362065 54362
32
Acetaminophen Approved Phase 4 103-90-2 1983
33
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 2 76-42-6 5284603
34
tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 1401-55-4
35
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
36
Rocuronium Approved Phase 4,Not Applicable 119302-91-9, 143558-00-3 441290
37
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
38
Alfuzosin Approved, Investigational Phase 4,Phase 3 81403-80-7 2092
39
Belladonna Approved, Experimental Phase 4
40
Morphine Approved, Investigational Phase 4,Not Applicable 57-27-2 5288826
41
Dexmedetomidine Approved, Vet_approved Phase 4,Not Applicable 113775-47-6 5311068 68602
42
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
43
Dopamine Approved Phase 4,Phase 2 62-31-7, 51-61-6 681
44
Nicotine Approved Phase 4,Not Applicable 54-11-5 89594 942
45
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 137-58-6 3676
46
Ofloxacin Approved Phase 4,Phase 3,Phase 1 82419-36-1 4583
47
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 1 100986-85-4 149096
48
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 93-14-1 3516
49
Gabapentin Approved, Investigational Phase 4,Phase 2,Phase 3 60142-96-3 3446
50
Methylene blue Approved, Investigational Phase 4 61-73-4

Interventional clinical trials:

(show top 50) (show all 1819)
# Name Status NCT ID Phase Drugs
1 A Prospective Study Comparing the Success Rate of Injection of (DefluxR) Versus (VantrisR) for VUR in Children Unknown status NCT02271035 Phase 4 Deflux;Vantris
2 Study Comparing Nitrofurantoin to Fosfomycin for Acute Urinary Tract Infection in Women Unknown status NCT01966653 Phase 4 nitrofurantoin;fosfomycin
3 Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes Unknown status NCT02540707 Phase 4 solifenacin;mirabegron
4 MIrabegron With oveRACtive bLadder Symptoms in mEn Unknown status NCT02361502 Phase 4 mirabegron;placebo
5 Botulinum Toxin in the Treatment of Idiopathic Detrusor Overactivity Unknown status NCT02009540 Phase 4 Botulinum toxin injected to bladder body;Botulinum toxin injected into trigone
6 Comparisons of 3-month Versus 6-month Solifenacin Treatment for Female OAB Patients Unknown status NCT01876186 Phase 4 Solifenacin for 12 weeks;Solifenacin for 24 weeks
7 Premarin Versus Toviaz for Treatment of Overactive Bladder Unknown status NCT01613170 Phase 4 Toviaz;Premarin;Placebo cream
8 Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder Unknown status NCT01423838 Phase 4 Solifenacin;Oxybutynin
9 Assessing the OAB-8 Questionnaire as a Tool to Measure Treatment Outcome Unknown status NCT00313924 Phase 4 DETRUSITOL
10 Surgical Treatment To Greater Anterior Vaginal Prolapse Unknown status NCT00676325 Phase 4
11 Influence of Immune Nutrition Diet on 90-Day Outcomes in Patients Undergoing Radical Cystectomy Unknown status NCT03147586 Phase 4 Bio-tech and omega-3 plus;placebo
12 Comparative Study of Mesh Versus No Mesh in Prolapse Surgery Unknown status NCT00153257 Phase 4
13 Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH) Unknown status NCT00922506 Phase 4 doxazosin plus tolterodine SR
14 Mebeverine For Daytime And Nocturnal Incontinence and After Orthotopic W-Ileal Neobladders Unknown status NCT03147599 Phase 4 Coloverin;Placebo
15 The Assessment of POCD After TURBT Under Spinal Anesthesia Unknown status NCT03029676 Phase 4 benzodiazepines;opioid
16 Effect of Botulinum Toxin in Neurogenic Bladders in Children With Myelomeningocele Unknown status NCT00175123 Phase 4 Botulinum A toxin
17 Clasic Laryngeal Mask Airway(C-LMA) and I-gel Releated Regurgitation and Complications Unknown status NCT01876836 Phase 4
18 Clinical Efficacy of Changing the InterStim® Parameters in Patients With Interstitial Cystitis/Painful Bladder Syndrome Unknown status NCT01312259 Phase 4
19 Botulinum A Toxin in the Treatment of Patients With Painful Bladder Syndrome Unknown status NCT01157507 Phase 4 Intravesical injection of Botulinum A Toxin;Placebo
20 Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns Completed NCT01930799 Phase 4
21 Intranasal Oxytocin for the Treatment of Pain Associated With Interstitial Cystitis Completed NCT00919802 Phase 4 Oxytocin
22 Efficacy of Oxybutynin in Paediatric Cystitis Completed NCT03877289 Phase 4 Oxybutynin
23 Intravesicular Onabotulinumtoxin A in Interstitial Cystitis Completed NCT02297100 Phase 4 Onabotulinumtoxin A
24 Intranasal Ketorolac Tromethamine (Sprix) for Acute Pain of Interstitial Cystitis Flare of Pain Completed NCT02000401 Phase 4 Ketorolac Tromethamine
25 Ibuprofen Versus Mecillinam for Uncomplicated Cystitis Completed NCT01849926 Phase 4 Ibuprofen;Mecillinam
26 A Pilot Comparison of Short-course Nitrofurantoin in Females With Uncomplicated Bacterial Cystitis in the Emergency Department Completed NCT01749605 Phase 4 Nitrofurantoin monohydrate/macrocrystals 100 mg BID x 3 days;ciprofloxacin 250 mg BID x 3 days
27 Botox as a Treatment for Interstitial Cystitis in Women Completed NCT00194610 Phase 4 Botox
28 Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1 Completed NCT01661621 Phase 4 Detrusitol 4 mg QD;Doxazosin 4 mg QD
29 Fall Prevention in Older Adults With OAB Completed NCT03946124 Phase 4 Fesoterodine
30 Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder Completed NCT03558919 Phase 4 Mirabegron 25mg;Solifenacin Succinate 5 MG
31 Investigation of the Effect of the Female Urinary Microbiome on Incontinence Completed NCT02835846 Phase 4 Estrogen Cream
32 Reproducibility Study of OABSS and Its Response to Treatment Completed NCT02667470 Phase 4 Solifenacin
33 Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event. Completed NCT02468375 Phase 4 mirabegron 50mg
34 Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron. Completed NCT02294396 Phase 4 Mirabegron tablet;Solifenacin tablet;Propiverine tablet;Imidafenacin tablet;Tolterodine capsule
35 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB) Completed NCT02216214 Phase 4 Mirabegron;Placebo
36 A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB) Completed NCT02138747 Phase 4 Mirabegron;Tolterodine ER
37 The Effect of Anticholinergics on Cognitive Function in the Elderly Completed NCT01922115 Phase 4 Trospium Chloride;Placebo
38 Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome Completed NCT01824420 Phase 4 Detrusitol 4mg QD and Oxybutynin ER 5mg QD;Detrusitol 4mg QD
39 A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients Completed NCT01745094 Phase 4 mirabegron;solifenacin
40 Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive Bladder Completed NCT01578304 Phase 4 Imidafenacin;Fesoterodine
41 The Efficacy of Solifenacin With or Without Tamsulosin in Adult Women With Overactive Bladder (OAB) Completed NCT01533597 Phase 4 Solifenacin;Solifenacin plus Tamsulosin
42 A Study to Evaluate Response of Over Active Bladder Symptom Score to Solifenacin Treatment Completed NCT01318837 Phase 4 solifenacin
43 Therapy of the Overactive Bladder Syndrome Completed NCT01314781 Phase 4 solifenacin
44 A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine Completed NCT01302067 Phase 4 Fesoterodine 8mg;Fesoterodine 4mg;Placebo
45 A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine. Completed NCT01302054 Phase 4 Fesoterodine 8 mg;Placebo
46 Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial Completed NCT01178827 Phase 4 trospium chloride;oxybutynin IR;oxybutynin IR placebo
47 Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder. Completed NCT01093534 Phase 4 Placebo;solifenacin
48 Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily Completed NCT01089751 Phase 4 trospium chloride;placebo
49 Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overactive Bladder Completed NCT01054222 Phase 4 Fesoterodine;Fesoterodine
50 Solifenacin Flexible Dosing Study in Frequent Micturition Patients With and Without Urgency Completed NCT00979472 Phase 4 Solifenacin

Search NIH Clinical Center for Bladder Disease

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Bladder Disease cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Bladder Disease:
Neo-Urinary Conduit, smooth muscle cell 3D culture for bladder diseases
Embryonic/Adult Cultured Cells Related to Bladder Disease:
Neo-Urinary Conduit� PMIDs: 22136657

Cochrane evidence based reviews: urinary bladder diseases

Sources

Genetic Tests for Bladder Disease

About this section
Sources

Anatomical Context for Bladder Disease

About this section

MalaCards organs/tissues related to Bladder Disease:

42
Prostate, Testes, Spinal Cord, Kidney, Lung, Brain, T Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Bladder Disease:

20
The Bladder
Sources

Publications for Bladder Disease

About this section

Articles related to Bladder Disease:

(show top 50) (show all 167)
# Title Authors Year
1
Hypoxic changes to the urothelium as a bystander of end-stage bladder disease. ( 30862459 )
2019
2
Characterization of voiding function and structural bladder changes in a rat model of neurogenic underactive bladder disease. ( 30105760 )
2018
3
Study on the Relation between Colorectal Cancer and Gall Bladder Disease. ( 28511430 )
2017
4
From gene discovery to new biological mechanisms: heparanases and congenital urinary bladder disease. ( 26315301 )
2016
5
Re: The Pharmacological rationale for combining muscarinic receptor antagonists and β-adrenoceptor agonists in the treatment of airway and bladder disease. ( 25523672 )
2015
6
Prognostic relevance of human telomerase reverse transcriptase (hTERT) expression in patients with gall bladder disease and carcinoma. ( 25854384 )
2015
7
Diagnosis of urinary bladder diseases in dogs by using two-dimensional and three-dimensional ultrasonography. ( 27047159 )
2015
8
Genetics of human congenital urinary bladder disease. ( 23584850 )
2014
9
The pharmacological rationale for combining muscarinic receptor antagonists and β-adrenoceptor agonists in the treatment of airway and bladder disease. ( 24682092 )
2014
10
Financial cost to institutions on patients waiting for gall bladder disease surgery. ( 25603667 )
2014
11
Gastric pouch after simple or radical cystectomy for benign and malignant bladder disease. ( 25738108 )
2014
12
Expression of microRNAs in urinary bladder samples obtained from dogs with grossly normal bladders, inflammatory bladder disease, or transitional cell carcinoma. ( 23013190 )
2012
13
Remodeling of the muscle layer (detrusor muscle) of hyperactive bladder disease in patients with benign prostatic hyperplasia. ( 23113284 )
2012
14
The role of sodium hyaluronate and sodium chondroitin sulphate in the management of bladder disease. ( 22046200 )
2011
15
Muscarinic Acetylcholine Receptor M3 Mutation Causes Urinary Bladder Disease and a Prune-Belly-like Syndrome. ( 22077972 )
2011
16
A murine model of inflammatory bladder disease: cathelicidin peptide induced bladder inflammation and treatment with sulfated polysaccharides. ( 21855919 )
2011
17
Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release. ( 19634167 )
2010
18
Prevalence and characteristics associated with self-reported gall bladder disease in Mexican American elders: results from the Hispanic Established Populations for Epidemiologic Studies in the Elderly (H-EPESE). ( 19225267 )
2009
19
A four-year-old with Streptococcus pneumoniae--associated hemolytic uremic syndrome and gall bladder disease necessitating cholecystectomy. ( 19286616 )
2009
20
Overactive bladder disease: the urge for better therapies. ( 18500915 )
2008
21
A study of the bacteriological pattern in gall bladder disease. 1986. ( 15485196 )
2004
22
Extracorporeal electromagnetic stimulation for urinary incontinence and bladder disease. ( 15088922 )
2003
23
In vivo optical coherence tomography feasibility for bladder disease. ( 11832776 )
2002
24
Oral cimetidine gives effective symptom relief in painful bladder disease: a prospective, randomized, double-blind placebo-controlled trial. ( 11167643 )
2001
25
Oral cimetidine gives effective symptom relief in painful bladder disease: a prospective, randomized, double-blind placebo-controlled trial. ( 11564042 )
2001
26
Electromagnetic pelvic floor stimulation for urinary incontinence and bladder disease. ( 11795645 )
2001
27
Bladder disease: A report based on the smooth muscle function in health and disease satellite meeting to the International Congress of Physiology. ( 12734603 )
2001
28
Review article: epidemiology of gall-bladder disease--role of intestinal transit. ( 10902996 )
2000
29
EAU - 15th Congress. Urinary incontinence and bladder disease. ( 16080050 )
2000
30
Nitric oxide synthase expression in neurogenic bladder disease: a pilot study. ( 10218094 )
1999
31
Diagnosis and localization of a complicated urinary tract infection in neurogenic bladder disease by tubular proteinuria and serum prostate specific antigen. ( 9471136 )
1998
32
Gall bladder disease and ABO blood group. ( 10456157 )
1997
33
Risk factors for symptomatic gall bladder disease. ( 7959216 )
1994
34
Long-term follow-up after clam ileocystoplasty. Complications and results including some quality-of-life parameters for 32 patients treated for neuropathic and nonneuropathic bladder disease. ( 8178380 )
1994
35
Cigarette smoking and parity as risk factors for the development of symptomatic gall bladder disease in women: results of the Royal College of General Practitioners' oral contraception study. ( 8307429 )
1994
36
Alterations to the electrophysiology of isolated human detrusor smooth muscle cells in bladder disease. ( 8309000 )
1994
37
Risk factors for the development of gall bladder disease. ( 18668936 )
1994
38
Is gallbladder ejection fraction a reliable predictor of acalculous gall bladder disease? ( 8321495 )
1993
39
Is gall bladder ejection fraction a reliable predictor of acalculous gall bladder disease? ( 1465273 )
1992
40
Superficial bladder disease: case studies and therapeutic advances. ( 1466118 )
1992
41
Gall bladder disease as seen in a Harare referral hospital centre. ( 2225019 )
1990
42
Gall bladder disease: an analytical report of 250 cases. ( 2634700 )
1989
43
Pancreatic cancer, alcohol, diabetes mellitus and gall-bladder disease. ( 2925272 )
1989
44
Looking for gall bladder disease in the patient's iris. ( 3147081 )
1988
45
Gall bladder disease in Zimbabwe. ( 3194957 )
1988
46
Parathyroid hormone like bioactivity measured by cytochemical bioassay in a patient with malignant bladder disease. ( 3248932 )
1988
47
A prospective double-blind clinically controlled multicenter trial of sodium pentosanpolysulfate in the treatment of interstitial cystitis and related painful bladder disease. ( 2442415 )
1987
48
Urine eosinophil cationic protein in painful bladder disease. ( 3304514 )
1987
49
Urinary excretion of a metabolite of histamine (1,4-methyl-imidazole-acetic-acid) in painful bladder disease. ( 3567484 )
1987
50
Painful bladder disease: clinical and pathoanatomical differences in 115 patients. ( 3625848 )
1987
Sources

Variations for Bladder Disease

About this section
Sources

Expression for Bladder Disease

About this section
Search GEO for disease gene expression data for Bladder Disease.
Sources

Pathways for Bladder Disease

About this section

Pathways related to Bladder Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Glioma 38
Show member pathways
 12.32 CDH1 CDKN2A FGFR3 HBEGF TP53
2
Gastric cancer 38
Show member pathways
 12.32 CDH1 CDKN2A GSTM1 TERT TP53
3
Pathways in cancer 38
12.16 CDH1 CDKN2A FGFR3 GSTM1 TERT TP53
4
Platinum drug resistance 38
11.41 CDKN2A GSTM1 TP53
5
Photodynamic therapy-induced AP-1 survival signaling. 1
11.04 CDKN2A HBEGF TP53
6
Bladder cancer 1 38
10.96 CDH1 CDKN2A FGFR3 HBEGF TP53 UPK3A
Sources

GO Terms for Bladder Disease

About this section

Cellular components related to Bladder Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.73 BLNK CD274 CDH1 CHRM3 FGFR3 HBEGF
2 integral component of plasma membrane GO:0005887 9.17 CHRM3 FGFR3 HBEGF SLC3A1 SLC7A9 TRPV1

Biological processes related to Bladder Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of interleukin-10 production GO:0032693 9.26 CD274 IDO1
2 L-cystine transport GO:0015811 9.16 SLC3A1 SLC7A9
3 L-alpha-amino acid transmembrane transport GO:1902475 9.02 SLC7A9
4 regulation of activated T cell proliferation GO:0046006 8.96 CD274 IDO1
5 replicative senescence GO:0090399 8.8 CDKN2A TERT TP53

Molecular functions related to Bladder Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein N-terminus binding GO:0047485 9.33 ERCC6 TERT TP53
2 L-cystine transmembrane transporter activity GO:0015184 8.96 SLC3A1 SLC7A9
3 disordered domain specific binding GO:0097718 8.8 CDKN2A NUMA1 TP53
Sources

Sources for Bladder Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....